Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study

References

• European Monitoring Centre for Drugs and Drug Addiction. United Kingdom country overview. 2016. http://www.emcdda.europa.eu/countries/united-kingdom#prevalence. Last accessed March 17, 2017
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. European drug report 2016: trends and developments. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction; 2016
   Google Scholar
• World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: WHO; 2009
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. The state of the drugs problem in Europe. Annual report 2011. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction; 2011
   Google Scholar
• Nielsen S, Larance B, Degenhardt L, et al. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev 2016;CD011117
   PubMed Web of Science ®Google Scholar
• Timko C, Schultz NR, Cucciare MA, et al. Retention in medication-assisted treatment for opiate dependence: A systematic review. J Addict Dis 2016;35:22-35
   PubMed Web of Science ®Google Scholar
• Low AJ, Mburu G, Welton NJ, et al. Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis. Clin Infect Dis 2016;63:1094-104
   PubMed Web of Science ®Google Scholar
• Cooper N, Coyle D, Abrams K, et al. Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997. J Health Serv Res Policy 2005;10:245-50
   PubMedGoogle Scholar
• Chetty M, Kenworthy JJ, Langham S, et al. A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence. Addict Sci Clin Pract 2017;12:6
   PubMed Web of Science ®Google Scholar
• Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-171, iii–iv
   PubMed Web of Science ®Google Scholar
• Tosh J, Wailoo A. Review of software for decision modelling. 2008. http://www.nicedsu.org.uk/PDFs of reports/softwarereport-final.pdf. Accessed 3rd March 2017
   Google Scholar
• Strathdee SA, Stockman JK. Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions. Curr HIV/AIDS Rep 2010;7:99-106
   PubMedGoogle Scholar
• Gossop M. The National Treatment Outcomes Research Study (NTORS) and its influence on addiction treatment policy in the United Kingdom. Addiction 2015;110:50-3
   PubMed Web of Science ®Google Scholar
• Godfrey C, Eaton G, McDougall C, et al. Home Office Research Study 249: The economic and social costs of Class A drug use in England and Wales, 2000. London: Development and Statistics Directorate; 2002
   Google Scholar
• Gossop M, Marsden J, Stewart D, et al. The National Treatment Outcome Research Study (NTORS): 4–5 year follow-up results. Addiction 2003;98:291-303
   PubMed Web of Science ®Google Scholar
• Gossop M, Marsden J, Stewart D, et al. Substance use, health and social problems of service users at 54 drug treatment agencies. Intake data from the National Treatment Outcome Research Study. Br J Psychiatry 1998;173:166-71
   PubMed Web of Science ®Google Scholar
• Webster L, Hjelmström P, Sumner M, et al. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial. J Addict Dis 2016;35:325-38
   PubMed Web of Science ®Google Scholar
• Nielsen S, Larance B, Degenhardt L, et al. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev 2016;CD011117
   PubMed Web of Science ®Google Scholar
• McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: What it is and what that means. Pharmacoeconomics 2008;26:733-44
   PubMed Web of Science ®Google Scholar
• Yarborough BJH, Stumbo SP, McCarty D, et al. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis. Drug Alcohol Depend 2016;160:112-18
   PubMed Web of Science ®Google Scholar
• Gowing L, Ali R, Dunlop A, et al. National guidelines for medication-assisted treatment of opioid dependence. 2014. Commonwealth of Australia, Canberra
   Google Scholar
• Ferri M, Minozzi S, Bo A, et al. Slow-release oral morphine as maintenance therapy for opioid dependence. Cochrane Database Syst Rev 2013;CD009879
   PubMed Web of Science ®Google Scholar
• Beck T, Haasen C, Verthein U, et al. Maintenance treatment for opioid dependence with slow-release oral morphine: A randomized cross-over, non-inferiority study versus methadone. Addiction 2014;109:617-26
   PubMed Web of Science ®Google Scholar
• Falcato L, Beck T, Reimer J, et al. Self-reported cravings for heroin and cocaine during maintenance treatment with slow-release oral morphine compared with methadone. J Clin Psychopharmacol 2015;35:150-7
   PubMed Web of Science ®Google Scholar
• Verthein U, Beck T, Haasen C, et al. Mental symptoms and drug use in maintenance treatment with slow-release oral morphine compared to methadone: results of a randomized crossover study. Eur Addict Res 2015;21:97-104
   PubMed Web of Science ®Google Scholar
• National Health Service Business Services Authority. NHS Prescription Services. 2016. http://www.nhsbsa.nhs.uk/PrescriptionServices.aspx. Accessed 7th March 2017
   Google Scholar
• British Medical Association, Royal Pharmaceutical Society. British National Formulary (BNF) 67. June. London: BMJ Group and Pharmaceutical Press; 2016
   Google Scholar
• Pharmaceutical Services Negotiating Committee. Fees and allowances 2016. http://psnc.org.uk/dispensing-supply/endorsement/fees-allowances/. Accessed 16th March 2017
   Google Scholar
• Thurrock Council. Supervised Consumption Primary Care Contact. 2016; https://www.thurrock.gov.uk/information-for-gps-and-pharmacies/supervised-consumption-primary-care-contracts. Accessed 3rd March 2017
   Google Scholar
• Curtis L. Unit costs of health and social care 2016. Canterbury: Persional Social Services Research Unit; 2016
   Google Scholar
• Department of Health. National schedule of reference costs (2015–2016). https://www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016. Accessed 7th March 2017
   Google Scholar
• Office for National Statistics. Consumer price inflation, September 2016. https://www.ons.gov.uk/economy/inflationandpriceindices/bulletins/consumerpriceinflation/sept2016. Accessed 7th March 2017
   Google Scholar
• Public Health England. Data tables of the unlinked anonymous monitoring survey of HIV and hepatitis in people who inject drugs. Surveillance update: July 2016. London: Public Health England; 2016
   Google Scholar
• Home Office. Drug misuse: findings from the 2015 to 2016 CSEW: data tables. 2016. https://www.gov.uk/government/statistics/drug-misuse-findings-from-the-2015-to-2016-csew. Accessed 3rd March 2017
   Google Scholar
• Office for National Statistics. Annual mid-year population estimates: mid 2015. Accessed 16th March 2017
   Google Scholar
• Public Health England. HIV diagnoses, late diagnoses and numbers accessing treatment and care: 2016 report. London: Public Health England; 2016
   Google Scholar
• Public Health England. Hepatitis C in the UK 2016 report. London: Public Health England; 2016
   Google Scholar
• Mandalia S, Mandalia R, Lo G, et al. Rising population cost for treating people living with HIV in the UK, 1997–2013. PLoS One 2010;5:e1577
   Web of Science ®Google Scholar
• National Institute of Health and Care Excellence. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Southampton: NIHCE; 2009
   Google Scholar
• Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015;61:77-87
   PubMed Web of Science ®Google Scholar
• Campos NG, Salomon JA, Servoss JC, et al. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med 2007;120:272-9
   PubMed Web of Science ®Google Scholar
• Barclay ST, Cooke GS, Holtham E, et al. A new paradigm evaluating cost per cure of HCV infection in the UK. Hepatol Med Policy 2016;1:2
   Google Scholar
• Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health 2000;90:1100-11
   PubMed Web of Science ®Google Scholar
• Ara R, Wailoo A. NICE DSU technical support document 12: the use of health state utility values in decision models. Sheffield; 2011. Decision Support Unit. School of Health and Related Research, University of Sheffield, UK
   Google Scholar
• Mrus JM, Sherman KE, Leonard AC, et al. Health values of patients coinfected with HIV/hepatitis C: are two viruses worse than one? Med Care 2006;44:158-66
   PubMed Web of Science ®Google Scholar